Relapsed data are uncompetitive, but the front-line PACC-mutant space offers hope.
ApexOnco Front Page
Recent articles
Cross-licensing pact brings in SKB105, and hands off China rights to CR-001 before first-in-human studies.
The THIO-104 study listing is live, along with questions about funding the trial.
The private US biotech features among recent first-in-human study entrants, with another PARP1-selective molecule.
Against the odds, the CD47 inhibitor now faces two more clinical catalysts.
Golcadomide will begin a new pivotal trial in follicular lymphoma.
The company will soon start a pivotal trial of its IL-12 gene therapy, but cash is short.
The group expects to raise nearly $170m.
